1137 related articles for article (PubMed ID: 27305904)
1. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
Mukherjee A; Velpandian T; Singla M; Kanhiya K; Kabra SK; Lodha R
Int J Tuberc Lung Dis; 2016 May; 20(5):666-72. PubMed ID: 27084822
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.
Martial LC; Kerkhoff J; Martinez N; Rodríguez M; Coronel R; Molinas G; Roman M; Gomez R; Aguirre S; Jongedijk E; Huisman J; Touw DJ; Pérez D; Chaparro G; Gonzalez F; Aarnoutse RE; Alffenaar JW; Magis-Escurra C
Int J Antimicrob Agents; 2018 Jul; 52(1):109-113. PubMed ID: 29751121
[TBL] [Abstract][Full Text] [Related]
4. Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?
Trentalange A; Borgogno E; Motta I; Antonucci M; Pirriatore V; Costa C; Rossi G; Barco A; De Nicolò A; Piccioni P; D'Avolio A; Bonora S; Di Perri G; Calcagno A
Int J Antimicrob Agents; 2021 Mar; 57(3):106297. PubMed ID: 33539932
[TBL] [Abstract][Full Text] [Related]
5. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of first-line tuberculosis drugs in Tanzanian patients.
Tostmann A; Mtabho CM; Semvua HH; van den Boogaard J; Kibiki GS; Boeree MJ; Aarnoutse RE
Antimicrob Agents Chemother; 2013 Jul; 57(7):3208-13. PubMed ID: 23629715
[TBL] [Abstract][Full Text] [Related]
7. Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers.
Xu J; Jin H; Zhu H; Zheng M; Wang B; Liu C; Chen M; Zhou L; Zhao W; Fu L; Lu Y
Clin Ther; 2013 Feb; 35(2):161-8. PubMed ID: 23410999
[TBL] [Abstract][Full Text] [Related]
8. Concentration-Dependent Antagonism and Culture Conversion in Pulmonary Tuberculosis.
Rockwood N; Pasipanodya JG; Denti P; Sirgel F; Lesosky M; Gumbo T; Meintjes G; McIlleron H; Wilkinson RJ
Clin Infect Dis; 2017 May; 64(10):1350-1359. PubMed ID: 28205671
[TBL] [Abstract][Full Text] [Related]
9. Serum Levels of Antituberculosis Drugs and Their Effect on Tuberculosis Treatment Outcome.
Park JS; Lee JY; Lee YJ; Kim SJ; Cho YJ; Yoon HI; Lee CT; Song J; Lee JH
Antimicrob Agents Chemother; 2016 Jan; 60(1):92-8. PubMed ID: 26459901
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring in the treatment of tuberculosis patients.
Magis-Escurra C; van den Boogaard J; Ijdema D; Boeree M; Aarnoutse R
Pulm Pharmacol Ther; 2012 Feb; 25(1):83-6. PubMed ID: 22179055
[TBL] [Abstract][Full Text] [Related]
11. Impact of nonlinear interactions of pharmacokinetics and MICs on sputum bacillary kill rates as a marker of sterilizing effect in tuberculosis.
Chigutsa E; Pasipanodya JG; Visser ME; van Helden PD; Smith PJ; Sirgel FA; Gumbo T; McIlleron H
Antimicrob Agents Chemother; 2015 Jan; 59(1):38-45. PubMed ID: 25313213
[TBL] [Abstract][Full Text] [Related]
12. Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.
Saktiawati AMI; Harkema M; Setyawan A; Subronto YW; Sumardi ; Stienstra Y; Aarnoutse RE; Magis-Escurra C; Kosterink JGW; van der Werf TS; Alffenaar JC; Sturkenboom MGG
Clin Pharmacokinet; 2019 Nov; 58(11):1445-1454. PubMed ID: 30997650
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of the First-Line Antituberculosis Drugs in Ghanaian Children with Tuberculosis with or without HIV Coinfection.
Antwi S; Yang H; Enimil A; Sarfo AM; Gillani FS; Ansong D; Dompreh A; Orstin A; Opoku T; Bosomtwe D; Wiesner L; Norman J; Peloquin CA; Kwara A
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27855070
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of Rifampin, Isoniazid, Pyrazinamide, and Ethambutol in Infants Dosed According to Revised WHO-Recommended Treatment Guidelines.
Bekker A; Schaaf HS; Draper HR; van der Laan L; Murray S; Wiesner L; Donald PR; McIlleron HM; Hesseling AC
Antimicrob Agents Chemother; 2016 Apr; 60(4):2171-9. PubMed ID: 26810651
[TBL] [Abstract][Full Text] [Related]
15. Determinants of serum concentration of first-line anti-tuberculosis drugs from China.
Lei Q; Wang H; Zhao Y; Dang L; Zhu C; Lv X; Wang H; Zhou J
Medicine (Baltimore); 2019 Oct; 98(41):e17523. PubMed ID: 31593125
[TBL] [Abstract][Full Text] [Related]
16. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
Babalik A; Ulus IH; Bakirci N; Kuyucu T; Arpag H; Dagyildizi L; Capaner E
Antimicrob Agents Chemother; 2013 Nov; 57(11):5740-2. PubMed ID: 23979746
[TBL] [Abstract][Full Text] [Related]
17. LC-MS/MS method for simultaneous quantification of the first-line anti-tuberculosis drugs and six primary metabolites in patient plasma: Implications for therapeutic drug monitoring.
Kivrane A; Grinberga S; Sevostjanovs E; Igumnova V; Pole I; Viksna A; Bandere D; Krams A; Cirule A; Pugovics O; Ranka R
J Chromatogr B Analyt Technol Biomed Life Sci; 2021 Nov; 1185():122986. PubMed ID: 34688197
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic drug monitoring in the treatment of tuberculosis.
Peloquin CA
Drugs; 2002; 62(15):2169-83. PubMed ID: 12381217
[TBL] [Abstract][Full Text] [Related]
19. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia.
Khan MY; Kinsara AJ; Osoba AO; Wali S; Samman Y; Memish Z
Int J Antimicrob Agents; 2001 May; 17(5):415-8. PubMed ID: 11337231
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.
Chirehwa MT; McIlleron H; Rustomjee R; Mthiyane T; Onyebujoh P; Smith P; Denti P
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28607022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
